JP2004217588A - Angiotensin-converting enzyme inhibitor - Google Patents
Angiotensin-converting enzyme inhibitor Download PDFInfo
- Publication number
- JP2004217588A JP2004217588A JP2003008131A JP2003008131A JP2004217588A JP 2004217588 A JP2004217588 A JP 2004217588A JP 2003008131 A JP2003008131 A JP 2003008131A JP 2003008131 A JP2003008131 A JP 2003008131A JP 2004217588 A JP2004217588 A JP 2004217588A
- Authority
- JP
- Japan
- Prior art keywords
- lys
- arg
- glu
- val
- gln
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000005541 ACE inhibitor Substances 0.000 title claims description 31
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 title claims description 31
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 title claims description 31
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 title claims description 31
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 82
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims abstract description 44
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims abstract description 44
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims abstract description 44
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 35
- 102000016349 Myosin Light Chains Human genes 0.000 claims abstract description 16
- 108010067385 Myosin Light Chains Proteins 0.000 claims abstract description 16
- 206010020772 Hypertension Diseases 0.000 claims abstract description 14
- 230000003301 hydrolyzing effect Effects 0.000 claims abstract description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 65
- 229920001184 polypeptide Polymers 0.000 claims description 60
- HEYHXPCPLIKJHL-UHFFFAOYSA-N Lys-Arg-Gln-Lys-Tyr-Asp-Ile Natural products NCCCCC(N)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCC(N)=O)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(O)=O)C(=O)NC(C(C)CC)C(O)=O)CC1=CC=C(O)C=C1 HEYHXPCPLIKJHL-UHFFFAOYSA-N 0.000 claims description 33
- PWAOSHVZEJZXDN-UHFFFAOYSA-N Glu-Lys-Glu-Arg-Glu-Arg-Gln Natural products OC(=O)CCC(N)C(=O)NC(CCCCN)C(=O)NC(CCC(O)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCC(O)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCC(N)=O)C(O)=O PWAOSHVZEJZXDN-UHFFFAOYSA-N 0.000 claims description 31
- 108010050508 Val-Lys-Lys-Val-Leu-Gly-Asn-Pro Proteins 0.000 claims description 31
- 125000000539 amino acid group Chemical group 0.000 claims description 29
- 150000001413 amino acids Chemical group 0.000 claims description 24
- 235000013305 food Nutrition 0.000 claims description 18
- 239000004480 active ingredient Substances 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 108091005804 Peptidases Proteins 0.000 claims description 7
- 239000004365 Protease Substances 0.000 claims description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 102000004903 Troponin Human genes 0.000 abstract description 25
- 108090001027 Troponin Proteins 0.000 abstract description 25
- 125000003275 alpha amino acid group Chemical group 0.000 abstract description 16
- 108090000284 Pepsin A Proteins 0.000 abstract description 9
- 102000057297 Pepsin A Human genes 0.000 abstract description 9
- 229940111202 pepsin Drugs 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 8
- 235000013372 meat Nutrition 0.000 abstract description 5
- 102000008934 Muscle Proteins Human genes 0.000 abstract description 3
- 108010074084 Muscle Proteins Proteins 0.000 abstract description 3
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 102000004987 Troponin T Human genes 0.000 description 15
- 108090001108 Troponin T Proteins 0.000 description 15
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 10
- 238000004007 reversed phase HPLC Methods 0.000 description 10
- -1 Alternatively Natural products 0.000 description 8
- 102000003505 Myosin Human genes 0.000 description 8
- 108060008487 Myosin Proteins 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 210000004899 c-terminal region Anatomy 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 6
- 102000035195 Peptidases Human genes 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 238000010829 isocratic elution Methods 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 235000015277 pork Nutrition 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 108090000317 Chymotrypsin Proteins 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229960002376 chymotrypsin Drugs 0.000 description 4
- 238000002523 gelfiltration Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 229960001322 trypsin Drugs 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 101800004538 Bradykinin Proteins 0.000 description 3
- 102400000967 Bradykinin Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 3
- 235000011130 ammonium sulphate Nutrition 0.000 description 3
- 230000003276 anti-hypertensive effect Effects 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- 102400000345 Angiotensin-2 Human genes 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000004278 EU approved seasoning Substances 0.000 description 2
- 208000007530 Essential hypertension Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000001919 adrenal effect Effects 0.000 description 2
- 229950006323 angiotensin ii Drugs 0.000 description 2
- 238000005571 anion exchange chromatography Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000004531 blood pressure lowering effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000020993 ground meat Nutrition 0.000 description 2
- 239000012145 high-salt buffer Substances 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 206010038464 renal hypertension Diseases 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 101000984728 Chiropsoides quadrigatus Angiotensin-converting enzyme inhibitory peptide Proteins 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- MMFKFJORZBJVNF-UWVGGRQHSA-N His-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 MMFKFJORZBJVNF-UWVGGRQHSA-N 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 108090000362 Lymphotoxin-beta Proteins 0.000 description 1
- 240000005856 Lyophyllum decastes Species 0.000 description 1
- 235000013194 Lyophyllum decastes Nutrition 0.000 description 1
- NTEVEUCLFMWSND-SRVKXCTJSA-N Lys-Arg-Gln Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O NTEVEUCLFMWSND-SRVKXCTJSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010070551 Meat Proteins Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102000013534 Troponin C Human genes 0.000 description 1
- 102000013394 Troponin I Human genes 0.000 description 1
- 108010065729 Troponin I Proteins 0.000 description 1
- YGKVNUAKYPGORG-AVGNSLFASA-N Tyr-Asp-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O YGKVNUAKYPGORG-AVGNSLFASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 235000015897 energy drink Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 210000002196 fr. b Anatomy 0.000 description 1
- 210000003918 fraction a Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 108010025306 histidylleucine Proteins 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/52—Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
【0001】
【発明の属する技術分野】
本発明は、アンギオテンシン変換酵素阻害剤又は高血圧予防用食品の有効成分として有用なポリペプチドに関する。
【0002】
【従来の技術】
アンギオテンシン変換酵素(ACE)は主にヒトの血管の内皮細胞、肺、腎臓及び脳に存在する。この酵素は、アンギオテンシンIに作用して、C末端から2つのアミノ酸(His−Leu)を切断することにより、強力な血圧上昇作用を有するアンギオテンシンIIに変換する。また、この酵素は、降圧作用のあるブラジキニンの分解にも関与している。
【0003】
従って、アンギオテンシン変換酵素の活性を阻害すれば、血圧が低下し、高血圧の予防乃至治療に効果を奏すると考えられる。
【0004】
これまでにも、種々のアンギオテンシン変換酵素阻害活性を有する物質が見出されている。
【0005】
例えば、牛乳等に含まれるカゼインやアサリ肉のタンパク質の分解物などが検討されている(例えば、特許文献1及び特許文献2参照)。しかし、これらは豚肉や牛肉などの畜肉に多く含まれる筋タンパク質を利用したものではない。
【0006】
また、畜肉由来のタンパク質の分解物も報告されている(非特許文献1参照)。しかし、十分なACE阻害作用を有するためには、ペプチドの付加等の修飾工程が必要であり、修飾工程等を伴わない天然由来のタンパク質で、満足のいく活性を有するものは未だ見出されていなかった。
【0007】
【特許文献1】
特開2001−106700
【0008】
【特許文献2】
特開平7−101985号公報
【0009】
【非特許文献1】
有原ら、「ミートサイエンス(meat science)」, 57, 319−324, (2001)
【0010】
【発明が解決しようとする課題】
本発明は、顕著なアンギオテンシン変換酵素(ACE)阻害活性を有し、天然物から得られ、毒性が低く安全性の高い物質を提供することを主な課題とする。
【0011】
【課題を解決するための手段】
本発明者は、新規なアンギオテンシン変換酵素(ACE)阻害活性を有する物質を見出すことを目的として鋭意検討を重ねた。その結果、粗精製トロポニン(分子量範囲約14〜31kDa、ミオシン軽鎖を含む)の酵素分解物に、顕著なアンギオテンシン変換酵素阻害活性を有する物質が存在することを見出し、更に検討を重ねて本発明を完成するに至った。
【0012】
即ち、本発明は次の事項に係る。
【0013】
本発明の第1項は、7〜10個のアミノ酸残基からなり、以下の3つのうちのいずれか1つのアミノ酸配列を有する、アンギオテンシン変換酵素阻害活性を有するポリペプチドに係る。
Val−Lys−Lys−Val−Leu−Gly−Asn−Pro;
Glu−Lys−Glu−Arg−Glu−Arg−Gln;
Lys−Arg−Gln−Lys−Tyr−Asp−Ile。
【0014】
好ましくは、
Val−Lys−Lys−Val−Leu−Gly−Asn−Proからなる8個のアミノ酸、
Val−Lys−Lys−Val−Leu−Gly−Asn−ProのN末端又はC末端に2個のアミノ酸残基が付加した10個のアミノ酸、
Glu−Lys−Glu−Arg−Glu−Arg−Gln又はLys−Arg−Gln−Lys−Tyr−Asp−Ileからなる7個のアミノ酸、或いは、Glu−Lys−Glu−Arg−Glu−Arg−Gln又はLys−Arg−Gln−Lys−Tyr−Asp−IleのN末端又はC末端に2個のアミノ酸残基が付加した9個のアミノ酸からなり、アンギオテンシン変換酵素阻害活性を有するポリペプチドに係る。
【0015】
より好ましくは、8〜10個のアミノ酸残基からなり、Val−Lys−Lys−Val−Leu−Gly−Asn−Proのアミノ酸配列を有する、ミオシン由来のアンギオテンシン変換酵素阻害活性を有するポリペプチド、
又は、7〜9個のアミノ酸残基からなり、Glu−Lys−Glu−Arg−Glu−Arg−Gln又はLys−Arg−Gln−Lys−Tyr−Asp−Ileのいずれかのアミノ酸配列を有する、トロポニンT由来のアンギオテンシン変換酵素阻害活性を有するポリペプチドに係る。
【0016】
更に具体的には、Val−Lys−Lys−Val−Leu−Gly−Asn−Proからなる8個のアミノ酸、又は、Val−Lys−Lys−Val−Leu−Gly−Asn−ProのN末端又はC末端に2個のアミノ酸残基が付加した10個のアミノ酸からなり、ミオシン由来のアンギオテンシン変換酵素阻害活性を有するポリペプチド、
或いは、Glu−Lys−Glu−Arg−Glu−Arg−Gln又はLys−Arg−Gln−Lys−Tyr−Asp−Ileからなる7個のアミノ酸、
或いは、Glu−Lys−Glu−Arg−Glu−Arg−Gln又はLys−Arg−Gln−Lys−Tyr−Asp−IleのN末端又はC末端に2個のアミノ酸残基が付加した9個のアミノ酸からなる、トロポニンT由来のアンギオテンシン変換酵素阻害活性を有するポリペプチドに係る。
【0017】
本発明の第2項は、5〜10個のアミノ酸残基からなり、以下の5つのうちいずれか1つのアミノ酸配列を有するポリペプチドを1種又は2種以上有効成分として含有するアンギオテンシン変換酵素阻害剤に係る。
Val−Lys−Lys−Val−Leu−Gly−Asn−Pro;
Val−Lys−Lys−Val−Leu−Gly−Asn−Pro−Ser−Asn;
Glu−Lys−Glu−Arg−Glu−Arg−Gln;
Lys−Arg−Gln−Lys−Tyr−Asp−Ile;
Lys−Arg−Gln−Lys−Tyr。
【0018】
好ましくは、以下の5つのポリペプチド;
Val−Lys−Lys−Val−Leu−Gly−Asn−Proからなるポリペプチド、
Val−Lys−Lys−Val−Leu−Gly−Asn−Pro−Ser−Asnからなるポリペプチド、
Glu−Lys−Glu−Arg−Glu−Arg−Glnからなるポリペプチド、
Lys−Arg−Gln−Lys−Tyr−Asp−Ileからなるポリペプチド、又は、
Lys−Arg−Gln−Lys−Tyrからなるポリペプチド
の1種又は2種以上を有効成分として含有するアンギオテンシン変換酵素阻害剤に係る。
【0019】
より好ましくは、以下のポリペプチド;
Val−Lys−Lys−Val−Leu−Gly−Asn−Proからなるミオシン由来のポリペプチド、
Val−Lys−Lys−Val−Leu−Gly−Asn−Pro−Ser−Asnからなるミオシン由来のポリペプチド、
Glu−Lys−Glu−Arg−Glu−Arg−GlnからなるトロポニンT由来のポリペプチド、
Lys−Arg−Gln−Lys−Tyr−Asp−IleからなるトロポニンT由来のポリペプチド、又は、
Lys−Arg−Gln−Lys−TyrからなるトロポニンT由来のポリペプチド
の1種又は2種以上を有効成分として含有するアンギオテンシン変換酵素阻害剤に係る。
【0020】
本発明の第3項は、粗精製トロポニン(分子量範囲約14〜31kDa、ミオシン軽鎖を含む)を、タンパク質分解酵素を用いて、7〜10個のアミノ酸残基からなり、以下の3つのうちの少なくとも1つのアミノ酸配列を有するポリペプチドに加水分解する工程を含むアンギオテンシン変換酵素阻害剤の製造方法に係る。
Val−Lys−Lys−Val−Leu−Gly−Asn−Pro;
Glu−Lys−Glu−Arg−Glu−Arg−Gln;
Lys−Arg−Gln−Lys−Tyr−Asp−Ile。
【0021】
好ましくは、粗精製トロポニン(分子量範囲約14〜31kDa、ミオシン軽鎖を含む)におけるミオシンを、タンパク質分解酵素を用いて、Val−Lys−Lys−Val−Leu−Gly−Asn−Proからなる8個のアミノ酸、又は、Val−Lys−Lys−Val−Leu−Gly−Asn−ProのN末端又はC末端に2個のアミノ酸残基が付加した10個のアミノ酸からなるポリペプチドに加水分解する工程を含むアンギオテンシン変換酵素阻害剤の製造方法に係る。
【0022】
または、粗精製トロポニン(分子量範囲約14〜31kDa、ミオシン軽鎖を含む)におけるトロポニンTを、タンパク質分解酵素を用いて、Glu−Lys−Glu−Arg−Glu−Arg−Gln又はLys−Arg−Gln−Lys−Tyr−Asp−Ileからなる7個のアミノ酸、或いは、Glu−Lys−Glu−Arg−Glu−Arg−Gln又はLys−Arg−Gln−Lys−Tyr−Asp−IleのN末端又はC末端に2個のアミノ酸残基が付加した9個のアミノ酸からなるポリペプチドに加水分解する工程を含むアンギオテンシン変換酵素阻害剤の製造方法に係る。
【0023】
好ましくは、粗精製トロポニン(分子量範囲約14〜31kDa、ミオシン軽鎖を含む)を、ペプシン、トリプシン又はキモトリプシンを用いて、7〜10個のアミノ酸残基からなり、以下の3つのうちの少なくとも1つのアミノ酸配列:
Val−Lys−Lys−Val−Leu−Gly−Asn−Pro;
Glu−Lys−Glu−Arg−Glu−Arg−Gln;
Lys−Arg−Gln−Lys−Tyr−Asp−Ile
を有するポリペプチドに加水分解する工程を含むアンギオテンシン変換酵素阻害剤の製造方法に係る。
【0024】
本発明の第4項は、アンギオテンシン変換酵素阻害剤が、5〜10個のアミノ酸残基からなり、以下の5つのうちいずれか1つのアミノ酸配列:
Val−Lys−Lys−Val−Leu−Gly−Asn−Pro;
Val−Lys−Lys−Val−Leu−Gly−Asn−Pro−Ser−Asn;
Glu−Lys−Glu−Arg−Glu−Arg−Gln;
Lys−Arg−Gln−Lys−Tyr−Asp−Ile;
Lys−Arg−Gln−Lys−Tyr
を有するポリペプチドの1種又は2種以上を有効成分として含有している、項3に記載の製造法に係る。
【0025】
好ましくは、粗精製トロポニン(分子量範囲約14〜31kDa、ミオシン軽鎖を含む)を、ペプシン、トリプシン又はキモトリプシンを用いて、7〜10個のアミノ酸残基からなり、以下の3つのうちの少なくとも1つのアミノ酸配列:
Val−Lys−Lys−Val−Leu−Gly−Asn−Pro;
Glu−Lys−Glu−Arg−Glu−Arg−Gln;
Lys−Arg−Gln−Lys−Tyr−Asp−Ile
を有するポリペプチドに加水分解する工程を含む、
5〜10個のアミノ酸残基からなり、以下の5つのうちいずれか1つのアミノ酸配列:
Val−Lys−Lys−Val−Leu−Gly−Asn−Pro;
Val−Lys−Lys−Val−Leu−Gly−Asn−Pro−Ser−Asn;
Glu−Lys−Glu−Arg−Glu−Arg−Gln;
Lys−Arg−Gln−Lys−Tyr−Asp−Ile;
Lys−Arg−Gln−Lys−Tyr
を有するポリペプチドの1種又は2種以上を有効成分として含有しているアンギオテンシン変換酵素阻害剤の製造方法に係る。
【0026】
本発明の第5項は、項1に記載のポリペプチド又は項2に記載のアンギオテンシン変換酵素阻害剤を有効成分として含有する高血圧予防用食品に係る。
【0027】
好ましくは、Val−Lys−Lys−Val−Leu−Gly−Asn−Proからなる8個のアミノ酸、又は、Val−Lys−Lys−Val−Leu−Gly−Asn−ProのN末端又はC末端に2個のアミノ酸残基が付加した10個のアミノ酸からなる、ミオシン由来のアンギオテンシン変換酵素阻害活性を有するポリペプチドを有効成分として含有する高血圧予防用食品に係る。
【0028】
または、Glu−Lys−Glu−Arg−Glu−Arg−Gln又はLys−Arg−Gln−Lys−Tyr−Asp−Ileからなる7個のアミノ酸、或いは、Glu−Lys−Glu−Arg−Glu−Arg−Gln又はLys−Arg−Gln−Lys−Tyr−Asp−IleのN末端又はC末端に2個のアミノ酸残基が付加した9個のアミノ酸からなる、トロポニンT由来のアンギオテンシン変換酵素阻害活性を有するポリペプチドを有効成分として含有する高血圧予防用食品に係る。
【0029】
【発明の実施の形態】
以下、本発明について詳細に説明する。
【0030】
ポリペプチド
本発明におけるポリペプチドは、7〜10個からなるアミノ酸残基からなり、以下の3つのうちいずれか1つの骨格を有し、アンギオテンシン変換酵素阻害活性を有するポリペプチドである。
Val−Lys−Lys−Val−Leu−Gly−Asn−Pro;
Glu−Lys−Glu−Arg−Glu−Arg−Gln;
Lys−Arg−Gln−Lys−Tyr−Asp−Ile。
【0031】
本発明のポリペプチドは、具体的には、
Val−Lys−Lys−Val−Leu−Gly−Asn−Proからなる8個のアミノ酸、
Val−Lys−Lys−Val−Leu−Gly−Asn−ProのN末端又はC末端に2個のアミノ酸残基が付加した10個のアミノ酸、
Glu−Lys−Glu−Arg−Glu−Arg−Gln又はLys−Arg−Gln−Lys−Tyr−Asp−Ileからなる7個のアミノ酸、或いは、Glu−Lys−Glu−Arg−Glu−Arg−Gln又はLys−Arg−Gln−Lys−Tyr−Asp−IleのN末端又はC末端に2個のアミノ酸残基が付加した9個のアミノ酸からなり、アンギオテンシン変換酵素阻害活性を有するポリペプチドである。
【0032】
上記骨格を有するポリペプチドが、優れたアンギオテンシン変換酵素阻害活性を有することが今回明らかとなった。
【0033】
ここで、Val−Lys−Lys−Val−Leu−Gly−Asn−Pro(VKKVLGNP)は、ミオシン軽鎖(Davoli et al. Animal Biotechnology, 8: 179−185, 1997)47位から54位由来のペプチドである。ミオシン由来のペプチドの中で、該ペプチドのように優れたアンギオテンシン変換酵素阻害活性を有するものはこれまで知られていなかった。
【0034】
また、Glu−Lys−Glu−Arg−Glu−Arg−Gln(EKERERQ)及びLys−Arg−Gln−Lys−Tyr−Asp−Ile(KRQKYDI)は、トロポニンT(Moir et al. Biochemical Journal, 161: 371−382, 1977)由来のペプチドと考えられる。
【0035】
トロポニンT由来のペプチドでアンギオテンシン変換酵素阻害活性を有するものはこれまで知られていなかった。
【0036】
上記本発明のポリペプチドは、粗精製トロポニン(分子量範囲約14〜31kDa、ミオシン軽鎖を含む)をタンパク質分解酵素で加水分解することによって得られる。粗精製トロポニンとしては、ウサギ、ウシ、ブタ等に由来するタンパク質から抽出したものを用いることができる。
【0037】
粗精製トロポニンは、具体的には、以下のような精製を行うことにより得られる。低塩濃度水溶液で洗浄したひき肉をアセトンパウダーにし、そこから高塩濃度バッファーで抽出する。抽出液に塩酸を加えpHを4.6とした後、遠心して得られた上清のpHをさらに水酸化カリウムで7.0に調整する。次いで、硫酸アンモニウムを加え、硫酸アンモニウム濃度40%から60%の間で沈殿してくる画分を集める。この沈殿を、バッファーを用いて透析することで、粗精製トロポニンを得る。
【0038】
タンパク質分解酵素としては、例えば、トリプシン、キモトリプシン、ペプシン等が挙げられる。
【0039】
タンパク質分解酵素による加水分解の条件は、適宜設定し得るが、トリプシン、キモトリプシンはpH7.0〜8.5、ペプシンはpH1〜3、また温度はいずれも25〜37℃とすることが一般的である。
【0040】
本発明のポリペプチドは、粗精製トロポニン(分子量範囲約14〜31kDa、ミオシン軽鎖を含む)をタンパク質加水分解酵素で加水分解した後、生成物を、イオン交換クロマトグラフィー、ゲルろ過クロマトグラフィー、逆相HPLCなどを適宜組み合わせて精製することにより得られる。
【0041】
また本発明のポリペプチドは、Fmoc固相合成などの公知の方法で合成してもよい。
【0042】
アンギオテンシン変換酵素阻害剤
本発明のアンギオテンシン変換酵素阻害剤は、上記アンギオテンシン変換酵素阻害活性を有するポリペプチドを1種または2種以上有効成分として含有することにより得られる。具体的には、7〜10個のアミノ酸残基からなり、以下の3つのうちいずれか1つの骨格を有するポリペプチドを1種又は2種以上有効成分として含有するアンギオテンシン変換酵素阻害剤である。
Val−Lys−Lys−Val−Leu−Gly−Asn−Pro;
Glu−Lys−Glu−Arg−Glu−Arg−Gln;
Lys−Arg−Gln−Lys−Tyr−Asp−Ile。
【0043】
本発明のアンギオテンシン変換酵素阻害剤においては、
Val−Lys−Lys−Val−Leu−Gly−Asn−Pro;
Glu−Lys−Glu−Arg−Glu−Arg−Gln;又は
Lys−Arg−Gln−Lys−Tyr−Asp−Ileのいずれかの骨格に適当なアミノ酸残基が付加したものやアミノ酸残基が欠如したものであって、アンギオテンシン変換酵素阻害活性を有するペプチドを有効成分として用いる。
【0044】
例えば、本発明には、5〜10個のアミノ酸残基からなり、以下の5つのうちいずれか1つの骨格を有するポリペプチドの1種又は2種以上を有効成分として含有するアンギオテンシン変換酵素阻害剤が含まれる。
Val−Lys−Lys−Val−Leu−Gly−Asn−Pro;
Val−Lys−Lys−Val−Leu−Gly−Asn−Pro−Ser−Asn;
Glu−Lys−Glu−Arg−Glu−Arg−Gln;
Lys−Arg−Gln−Lys−Tyr−Asp−Ile;
Lys−Arg−Gln−Lys−Tyr。
【0045】
ここで、Val−Lys−Lys−Val−Leu−Gly−Asn−Pro−Ser−Asn(VKKVLGNPSN)は、VKKVLGNPに2個のアミノ残基が付加したものであり、ミオシン軽鎖の47位から56位に相当する。
【0046】
また、Lys−Arg−Gln−Lys−Tyr(KRQKY)は、KRQKYDIから2個のアミノ酸残基が欠如したものである。
【0047】
アンギオテンシン変換酵素阻害剤は、上記に例示したポリペプチドをそのまま又は適当な担体と共に適宜製剤化することによって得ることができる。
【0048】
担体としては、製剤分野において常用され、かつ本発明のポリペプチドと反応しない物質を用いることができる。
【0049】
具体的には、例えば乳糖、ブドウ糖、マンニット、デキストリン、シクロデキストリン、テンプン、庶糖、メタケイ酸アルミン酸マグネシウム、合成ケイ酸アルミニウム、カルボキシメチルセルロースナトリウム、ヒドロキシプロピルデンプン、カルボキシメチルセルロースカルシウム、イオン交換樹脂、メチルセルロース、ゼラチン、アラビアゴム、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、ポリビニルピロリドン、ポリビニルアルコール、軽質無水ケイ酸、ステアリン酸マグネシウム、タルク、トラガント、ベントナイト、ビーガム、酸化チタン、ソルビタン脂肪酸エステル、ラウリル硫酸ナトリウム、グリセリン、脂肪酸グリセリンエステル、精製ラノリン、グリセロゼラチン、ポリソルベート、マクロゴール、植物油、ロウ、流動パラフィン、白色ワセリン、フルオロカーボン、非イオン界面活性剤、プロピレングリコール、水等が挙げられる。剤型としては、錠剤、カプセル剤、顆粒剤、散剤、シロップ剤、懸濁剤、坐剤、軟膏、クリーム剤、ゲル剤、貼付剤、吸入剤、注射剤等が挙げられる。尚、液体製剤にあっては、用時、水又は他の適当な媒体に溶解又は懸濁する形であってもよい。また錠剤、顆粒剤は周知の方法でコーティングしてもよい。注射剤の場合には、ポリペプチドを水、生理食塩水あるいはブドウ糖溶液等に溶解させてもよい。また緩衝剤や保存剤を添加してもよい。
【0050】
本発明のアンギオテンシン変換酵素阻害剤における、上記ポリペプチドの含有量は所望に応じて適宜設定し得るが、0.0001〜100%程度、好ましくは0.01〜10%程度の割合で含有する。
【0051】
本発明のアンギオテンシン変換酵素阻害剤には、降圧作用を有する他の成分や各種の添加剤を含有させてもよい。
【0052】
本発明のアンギオテンシン変換酵素阻害剤は、血圧降下作用、ブラジキニン不活化抑制作用を奏し得ることから、本態性高血圧、腎性高血圧、副腎性高血圧などの高血圧症の予防乃至治療剤、狭心病発作の閾値上昇、心筋梗塞の減少、うっ血性心不全における病態の改善剤等として用いることができる。
【0053】
高血圧予防用食品
本発明の高血圧予防用食品は、上記本発明のポリペプチド又はアンギオテンシン変換酵素阻害剤を適当な食材に含有させることにより得ることができる。
【0054】
食材としては、例えば、豚肉、牛肉、家兎肉(ウサギ)、羊肉、山羊肉、馬肉、鶏肉、七面鳥肉、ウズラ肉、鯨肉、サメ肉、タラやサケといった魚肉類等が挙げられる。
【0055】
食品の形態としては、ソーセージ、ハム、ハンバーグ、ミートボールなどの畜肉加工品、カレー、コロッケ、鶏肉唐揚げ、春巻き、ロールキャベツなどの惣菜類、スープ類、栄養ドリンク類、ゼリー、アイスクリームなどのデザート類、スナック・菓子類、錠剤タイプの栄養機能食品類、唐揚げ粉などの混合調味料類、粉末調味料類等が挙げられる。
【0056】
本発明の食品においては、上記ポリペプチド又はアンギオテンシン変換酵素阻害剤は、いずれかのアミノ酸骨格を有するものを、1種単独で、又は2種以上を併用して用いることができる。
【0057】
本発明の食品におけるポリペプチド又はアンギオテンシン変換酵素阻害剤の含有量は、所望に応じて適宜設定し得るが、ポリペプチドとして0.0001〜99%程度、好ましくは0.01〜10%程度である。
【0058】
本発明の食品には、降圧作用を有する他の成分や食品に一般に用いられる添加剤、例えばソルビン酸などの保存料、リン酸塩などの結着補強剤、カラギーナンなどの増粘剤、ビタミンCなどの強化剤、亜硝酸ナトリウムなどの発色剤、安定剤、酸化防止剤、固結防止剤等を適宜含有していてもよい。
【0059】
本発明の食品は、上記ポリペプチド及び該ポリペプチドを含有するアンギオテンシン変換酵素阻害剤を含んでいることから、アンギオテンシン変換酵素(ACE)阻害活性を有し、強力な血圧上昇作用を有するアンギオテンシンIIの変換阻害作用や降圧作用のあるブラジキニンの分解阻害作用に基づく血圧降下作用を奏する。
【0060】
このような性質から、本発明は、本態性高血圧、腎性高血圧、副腎性高血圧などの高血圧症の予防用食品として、好適に用いることができる。
【0061】
【実施例】
以下、実施例を示して本発明を具体的に説明するが、本発明はこれらの実施例に限定されるものではない。
【0062】
実施例1
国産の豚ロース肉から抽出した粗精製トロポニン(分子量範囲約14〜31kDa)をペプシンで加水分解した。粗精製トロポニンは、以下のような精製を行うことにより得た。低塩濃度水溶液(1% トライトン X−100, 50 mM 塩化カリウム, 5 mM トリス(ヒドロキシメチル)アミノメタン, pH 8.0)で洗浄したひき肉をアセトンパウダーにし、そこから高塩濃度バッファー(1 M塩化カリウム, 25 mM トリス(ヒドロキシメチル)アミノメタン, 0.1 mM 塩化カルシウム, 0.1 mM ジチオトレイトール, 1 mM アジ化ナトリウム, pH 8.0)の溶液で抽出した。抽出液に塩酸を加えpHを4.6とした後、遠心して得られた上清のpHをさらに水酸化カリウムで7.0に調整して硫酸アンモニウムを加え、硫酸アンモニウム濃度40%から60%の間で沈殿してくる画分を集めた。この沈殿をバッファー(2 mM トリス(ヒドロキシメチル)アミノメタン, 0.5 mMジチオトレイトール, 2 mM アジ化ナトリウム, pH 7.5)に透析することで、粗精製トロポニンを得た。
【0063】
なお、この粗精製トロポニンにはミオシン軽鎖(分子量約15〜26kDa)が含まれていることが、ポリアクリルアミド電気泳動により確認された。この粗精製トロポニンのペプシン加水分解物のウシ肺由来のACEに対する50%阻害活性(IC50)は225 mg/mlであった。未加水分解トロポニンにはACE阻害活性が認められなかったことから、活性の発現はペプシン分解で生じたペプチドに由来することが推定された。
【0064】
以下、実施例1において、アンギオテンシン変換酵素(ACE)に対する50%阻害活性(IC50)は、ウシ肺由来ACEを用いて、Cushman− Cheungの方法(Biochemical Pharmacology, 20: 1637−1648, 1971)で測定した。
【0065】
該加水分解物をまず、DE53カラム(Whatman International Ltd., Kent, UK) (16 x 150 mm)を用いる陰イオン交換クロマトグラフィーに供した。すなわち、20mMトリス(ヒドロキシメチル)アミノメタン(酢酸でpH 7.5に調整したもの)で該加水分解物をアプライし、同バッファーを含むNaCl水溶液によるグラジェント(0−300 mM)溶出を行った。流速は1.13 ml/分とし、7分毎(7.91 ml)に分画したのち、215 nmと280 nmの吸光度を測定した(図1)。得られた画分をSEP−PAK PlusC18カートリッジ(Waters Co., Milford, MA, USA)を用いて脱塩し、吸着画分を50%アセトニトリルで溶出させて得られた画分を濃縮して、その活性を測定した。特に強い活性が認められたのは、初期に溶出した画分(IC50 = 201 mg/ml)であった。この活性画分をコスモシール5C18 AR−II (4.5 x 150 mm) (Nacalai Tesque Inc., Kyoto, Japan)を用いる逆相(RP)−HPLCに供し、0.1%トリフルオロ酢酸(TFA)を含むアセトニトリルの1−80%のグラジェント溶出(流速0.5 ml/分)で分画し、215 nmの吸光度をモニターした(図2)。以降の精製過程でも215 nmの吸光度を測定した。
【0066】
次に、図2のフラクション5 (IC50 = 138 mg/ml)をコスモシール5C18 AR−II (4.5 x 150 mm) (Nacalai Tesque)を用いるRP−HPLCに供し、0.1% TFAを含む12% CH3CNでイソクラティック溶出(流速0.5 ml/min)した(図3)。ここで得られた活性画分AおよびBをTSK−gel G2000SWXL (7.8 x 300 mm) (Tosoh Co., Tokyo, Japan)を用いるゲルろ過HPLCにそれぞれ供して、20 mMリン酸ナトリウム(pH 7.0)でイソクラティック溶出(流速0.5 ml/min)した(図4)。ここで得られた活性の強い画分(A由来: IC50 = 119 mg/ml, B由来: IC50 = 27 mg/ml)をコスモシール5PE−MS (4.6 x 250 mm) (Nacalai Tesque)を用いるRP−HPLCに供し、0.1% TFAを含む12% CH3CNでイソクラティック溶出(流速1 ml/min)した。同カラムでさらに二回繰り返し精製(12%および14% CH3CN)することで単一と認められるピークをそれぞれ得た(図5)。
【0067】
さらに、図2のフラクション7 (IC50 = 114 mg/ml)をコスモシール5C18 AR−II(4.5 x 150 mm) (Nacalai Tesque)を用いるRP−HPLCに供し、0.1% TFAを含む16%CH3CNでイソクラティック溶出(流速0.5 ml/min)した(図6)。ここで得られた活性画分LをTSK−gel G2000SWXL (7.8 x 300 mm) (Tosoh)を用いるゲルろ過HPLCに供して、20 mMリン酸ナトリウム(pH 7.0)でイソクラティック溶出(流速0.5 ml/min)した(図7)。ここで得られた活性の強い画分(L由来: IC50 = 57 mg/ml)をコスモシール 5PE−MS (4.6 x 250 mm) (Nacalai Tesque)を用いるRP−HPLCに供し、0.1% TFAを含む15% CH3CNでイソクラティック溶出(流速1 ml/min)した。同カラムでさらに二回繰り返し精製(12% CH3CNを二回)することで単一と認められるピークを得た(図8)。
【0068】
精製で得られた画分のアミノ酸配列を、プロテインシーケンサーProcise 492 (Applied Biosystems, Foster City, CA, USA)でシーケンス解析した。その結果、画分Aから得られたペプチドはVKKVLGNP、画分Bから得られたペプチドはEKERERQ、画分Lから得られたペプチドはKRQKYDIであると認められた。これらのペプチドはこれまでに報告のない、新規なACE阻害ペプチドであった。
これらのアミノ酸配列をデータベースSwissProt (EMBL Outstation− European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SD, UK)で検索した結果、VKKVLGNPは豚のミオシン軽鎖の47位から54位に一致し、材料として使用した粗精製トロポニンに含まれていたミオシン軽鎖(分子量約15〜26kDa)由来と認められた。EKERERQおよびKRQKYDIは、ウサギ、ウシ、ラット、ヒト、マウスの骨格筋トロポニンTに含まれるペプチドと一致した。
【0069】
本発明で利用した粗精製トロポニン(分子量範囲約14〜31kDa、ミオシン軽鎖を含む)は豚骨格筋由来のものであるが、豚トロポニンの配列はトロポニンC、トロポニンI、トロポニンTとも、未だ確定していない。データベースには豚トロポニンCのアミノ酸配列が一応登録されてはいるものの、トロポニンIおよびトロポニンTのアミノ酸配列は登録されておらず、本発明のペプチドと完全に一致する配列は見出せなかった。しかし、豚以外の動物のトロポニンのアミノ酸配列がデータベースに登録されているため、本研究で得られたペプチドがこれらのトロポニン中に存在するかどうかを検索した。その結果、EKERERQは、ウサギ(120〜126残基目)、ウシ(120〜126残基目)、ラット(102〜108残基目)、ヒト(112〜118残基目)、マウス(104〜110残基目)のトロポニンTに存在していた。また、KRQKYDIはウサギ(230〜236残基目)、ウシ(230〜236残基目)、ラット(212〜218残基目)、ヒト(222〜228残基目)、マウス(214〜220残基目)のトロポニンTに存在していた。これらのことから豚のトロポニンTにも同じ配列のペプチドが存在している可能性が認められ、本研究で見出したペプチドは豚肉を材料として得られたものであるため、トロポニンT由来であると推定された。
【0070】
実施例2
実施例1で同定したACE阻害ペプチド3種類と、その関連ペプチドであるVKKVLGNPSN(豚ミオシン軽鎖の47位から56位に相当)とKRQKY(ウサギトロポニンTの230位から234位に相当)をFmoc固相合成法で合成した。
【0071】
ACE 阻害活性の評価
実施例2で作成したペプチドのIC50、分子量、及びRP−HPLC((TSKgel ODS−80TS、 4.5 x 250 mm、Tosoh)で0.1% TFAを含むアセトニトリルの5−55% (20分)のグラジェント溶出(流速1 ml/min))の保持時間(RT)を表1に示す。
【0072】
実施例2において、ACEに対する50%阻害活性(IC50)は、ウサギ肺由来のACEを用いて、Cushman− Cheungの方法(Biochemical Pharmacology, 20: 1637−1648, 1971)で測定した。
【0073】
【表1】
【0074】
【発明の効果】
本発明は、豚肉や牛肉に多く含まれる筋タンパク質であるトロポニンやミオシンから得られる、新規なアンギオテンシン変換酵素(ACE)阻害活性を有するポリペプチドを提供するものである。
【0075】
本発明のポリペプチド乃至アンギオテンシン変換酵素阻害剤は、顕著なアンギオテンシン変換酵素阻害活性を有するだけでなく、天然の食肉由来のタンパク質を生体内にも存在する消化酵素を用いて分解して得られることから、安全性が高く、毒性も低い。
【0076】
このような特性により、本発明のポリペプチド乃至アンギオテンシン変換酵素阻害剤は、医薬用の薬理成分として有用であるばかりでなく、血圧降下作用等を有する高血圧予防用食品等の付加価値の高い機能性食品を作る素材としても有用である。
【図面の簡単な説明】
【図1】図1は、粗精製トロポニンのペプシン加水分解物を試料とする陰イオン交換クロマトグラフィーを行った際に得られたクロマトグラムを示す図である。
【図2】図2は、図1に示される活性画分をコスモシール(Cosmosil)5C18 AR−IIを用いる逆相高速液体クロマトグラフィーに供した際のクロマトグラムを示す図である。
【図3】図3は、図2に示される活性画分5を再度コスモシール5C18 AR−IIを用いる逆相高速液体クロマトグラフィーに供した際のクロマトグラムを示す図である。
【図4】図4は、図3に示される活性画分AおよびBをそれぞれTSK−gel G2000SWXLを用いるゲル濾過高速液体クロマトグラフィーに供した際のクロマトグラムを示す図である。
【図5】図5は、図4に示されるふたつの活性画分(画分AおよびB由来)をそれぞれコスモシール 5PE−MSを用いる逆相高速液体クロマトグラフィーに供した際のクロマトグラムを示す図である。
【図6】図6は、図2に示される活性画分7を再度コスモシール5C18 AR−IIを用いる逆相高速液体クロマトグラフィーに供した際のクロマトグラムを示す図である。
【図7】図7は、図6に示される活性画分LをTSK−gel G2000SWXLを用いるゲル濾過高速液体クロマトグラフィーに供した際のクロマトグラムを示す図である。
【図8】図8は、図7に示される活性画分(画分L由来)をコスモシール 5PE−MSを用いる逆相高速液体クロマトグラフィーに供した際のクロマトグラムを示す図である。[0001]
TECHNICAL FIELD OF THE INVENTION
The present invention relates to a polypeptide useful as an angiotensin converting enzyme inhibitor or an active ingredient of a food for preventing hypertension.
[0002]
[Prior art]
Angiotensin converting enzyme (ACE) is present mainly in human vascular endothelial cells, lung, kidney and brain. This enzyme acts on angiotensin I to cleave two amino acids (His-Leu) from the C-terminus, thereby converting it into angiotensin II having a strong blood pressure increasing effect. This enzyme is also involved in the degradation of antihypertensive bradykinin.
[0003]
Therefore, if the activity of the angiotensin converting enzyme is inhibited, it is considered that the blood pressure is reduced, which is effective in preventing or treating hypertension.
[0004]
Until now, various substances having angiotensin converting enzyme inhibitory activity have been found.
[0005]
For example, casein and clam meat protein degradation products contained in milk and the like have been studied (for example, see
[0006]
In addition, a degradation product of a protein derived from livestock meat has been reported (see Non-Patent Document 1). However, in order to have a sufficient ACE inhibitory action, a modification step such as addition of a peptide is required, and a naturally occurring protein having no modification step and the like having a satisfactory activity has been found. Did not.
[0007]
[Patent Document 1]
JP 2001-106700A
[0008]
[Patent Document 2]
JP-A-7-101985
[0009]
[Non-patent document 1]
Arihara et al., "Meat Science", 57, 319-324, (2001).
[0010]
[Problems to be solved by the invention]
An object of the present invention is to provide a substance which has remarkable angiotensin converting enzyme (ACE) inhibitory activity, is obtained from natural products, has low toxicity and high safety.
[0011]
[Means for Solving the Problems]
The present inventors have conducted intensive studies for the purpose of finding a substance having a novel angiotensin converting enzyme (ACE) inhibitory activity. As a result, it was found that a substance having remarkable angiotensin converting enzyme inhibitory activity was present in the enzymatically degraded product of partially purified troponin (molecular weight range: about 14 to 31 kDa, including myosin light chain). Was completed.
[0012]
That is, the present invention relates to the following matters.
[0013]
The first item of the present invention relates to a polypeptide having an angiotensin converting enzyme inhibitory activity, comprising 7 to 10 amino acid residues and having any one of the following three amino acid sequences.
Val-Lys-Lys-Val-Leu-Gly-Asn-Pro;
Glu-Lys-Glu-Arg-Glu-Arg-Gln;
Lys-Arg-Gln-Lys-Tyr-Asp-Ile.
[0014]
Preferably,
8 amino acids consisting of Val-Lys-Lys-Val-Leu-Gly-Asn-Pro,
10 amino acids obtained by adding two amino acid residues to the N-terminal or C-terminal of Val-Lys-Lys-Val-Leu-Gly-Asn-Pro;
7 amino acids consisting of Glu-Lys-Glu-Arg-Glu-Arg-Gln or Lys-Arg-Gln-Lys-Tyr-Asp-Ile, or Glu-Lys-Glu-Arg-Glu-Arg-Gln or The present invention relates to a polypeptide comprising nine amino acids with two amino acid residues added to the N-terminal or C-terminal of Lys-Arg-Gln-Lys-Tyr-Asp-Ile and having angiotensin converting enzyme inhibitory activity.
[0015]
More preferably, a polypeptide consisting of 8 to 10 amino acid residues, having an amino acid sequence of Val-Lys-Lys-Val-Leu-Gly-Asn-Pro, having a myosin-derived angiotensin converting enzyme inhibitory activity,
Or, a troponin consisting of 7 to 9 amino acid residues and having any amino acid sequence of Glu-Lys-Glu-Arg-Glu-Arg-Gln or Lys-Arg-Gln-Lys-Tyr-Asp-Ile. The present invention relates to a T-derived polypeptide having an angiotensin converting enzyme inhibitory activity.
[0016]
More specifically, eight amino acids consisting of Val-Lys-Lys-Val-Leu-Gly-Asn-Pro, or N-terminal or C-terminal of Val-Lys-Lys-Val-Leu-Gly-Asn-Pro A polypeptide consisting of 10 amino acids with two amino acid residues added to the terminus and having angiotensin converting enzyme inhibitory activity derived from myosin;
Alternatively, 7 amino acids consisting of Glu-Lys-Glu-Arg-Glu-Arg-Gln or Lys-Arg-Gln-Lys-Tyr-Asp-Ile,
Alternatively, Glu-Lys-Glu-Arg-Glu-Arg-Gln or Lys-Arg-Gln-Lys-Tyr-Asp-Ile has 9 amino acids with two amino acid residues added to the N-terminus or C-terminus. The present invention relates to a polypeptide having troponin T-derived angiotensin converting enzyme inhibitory activity.
[0017]
Item 2 of the present invention is an angiotensin converting enzyme inhibitor comprising 5 to 10 amino acid residues and containing one or more active ingredients of a polypeptide having any one of the following five amino acid sequences: Pertaining to the agent.
Val-Lys-Lys-Val-Leu-Gly-Asn-Pro;
Val-Lys-Lys-Val-Leu-Gly-Asn-Pro-Ser-Asn;
Glu-Lys-Glu-Arg-Glu-Arg-Gln;
Lys-Arg-Gln-Lys-Tyr-Asp-Ile;
Lys-Arg-Gln-Lys-Tyr.
[0018]
Preferably, the following five polypeptides;
A polypeptide consisting of Val-Lys-Lys-Val-Leu-Gly-Asn-Pro,
A polypeptide consisting of Val-Lys-Lys-Val-Leu-Gly-Asn-Pro-Ser-Asn;
A polypeptide consisting of Glu-Lys-Glu-Arg-Glu-Arg-Gln;
A polypeptide consisting of Lys-Arg-Gln-Lys-Tyr-Asp-Ile, or
Polypeptide consisting of Lys-Arg-Gln-Lys-Tyr
The present invention relates to an angiotensin converting enzyme inhibitor comprising one or more of the following as an active ingredient.
[0019]
More preferably, the following polypeptides;
A myosin-derived polypeptide consisting of Val-Lys-Lys-Val-Leu-Gly-Asn-Pro;
A myosin-derived polypeptide consisting of Val-Lys-Lys-Val-Leu-Gly-Asn-Pro-Ser-Asn;
A troponin T-derived polypeptide consisting of Glu-Lys-Glu-Arg-Glu-Arg-Gln;
A troponin T-derived polypeptide consisting of Lys-Arg-Gln-Lys-Tyr-Asp-Ile, or
Troponin T-derived polypeptide consisting of Lys-Arg-Gln-Lys-Tyr
The present invention relates to an angiotensin converting enzyme inhibitor comprising one or more of the following as an active ingredient.
[0020]
The third item of the present invention is that crude troponin (molecular weight range of about 14 to 31 kDa, including myosin light chain) is composed of 7 to 10 amino acid residues using a proteolytic enzyme. The present invention relates to a method for producing an angiotensin converting enzyme inhibitor, which comprises a step of hydrolyzing to a polypeptide having at least one amino acid sequence of
Val-Lys-Lys-Val-Leu-Gly-Asn-Pro;
Glu-Lys-Glu-Arg-Glu-Arg-Gln;
Lys-Arg-Gln-Lys-Tyr-Asp-Ile.
[0021]
Preferably, myosin in the crudely purified troponin (molecular weight range: about 14 to 31 kDa, including myosin light chain) is converted into eight varieties of Val-Lys-Lys-Val-Leu-Gly-Asn-Pro using a protease. Or a step of hydrolyzing to a polypeptide consisting of 10 amino acids with two amino acid residues added to the N-terminus or C-terminus of Val-Lys-Lys-Val-Leu-Gly-Asn-Pro. And a method for producing an angiotensin converting enzyme inhibitor.
[0022]
Alternatively, troponin T in crude troponin (molecular weight range of about 14 to 31 kDa, including myosin light chain) can be converted to Glu-Lys-Glu-Arg-Glu-Arg-Gln or Lys-Arg-Gln using a protease. 7 amino acids consisting of -Lys-Tyr-Asp-Ile, or N-terminal or C-terminal of Glu-Lys-Glu-Arg-Glu-Arg-Gln or Lys-Arg-Gln-Lys-Tyr-Asp-Ile The present invention relates to a method for producing an angiotensin converting enzyme inhibitor, which comprises a step of hydrolyzing to a polypeptide consisting of 9 amino acids obtained by adding two amino acid residues to a polypeptide.
[0023]
Preferably, crude troponin (molecular weight range of about 14-31 kDa, including myosin light chain) is composed of 7-10 amino acid residues using pepsin, trypsin or chymotrypsin and comprises at least one of the following three: Two amino acid sequences:
Val-Lys-Lys-Val-Leu-Gly-Asn-Pro;
Glu-Lys-Glu-Arg-Glu-Arg-Gln;
Lys-Arg-Gln-Lys-Tyr-Asp-Ile
The present invention relates to a method for producing an angiotensin converting enzyme inhibitor, which comprises a step of hydrolyzing to a polypeptide having
[0024]
Item 4 of the present invention is that the angiotensin converting enzyme inhibitor comprises 5 to 10 amino acid residues, and has one of the following five amino acid sequences:
Val-Lys-Lys-Val-Leu-Gly-Asn-Pro;
Val-Lys-Lys-Val-Leu-Gly-Asn-Pro-Ser-Asn;
Glu-Lys-Glu-Arg-Glu-Arg-Gln;
Lys-Arg-Gln-Lys-Tyr-Asp-Ile;
Lys-Arg-Gln-Lys-Tyr
Item 4 relates to the production method according to Item 3, which comprises one or more of the polypeptides having the following as an active ingredient:
[0025]
Preferably, the crude troponin (molecular weight range of about 14-31 kDa, including myosin light chain) is composed of 7-10 amino acid residues using pepsin, trypsin or chymotrypsin and comprises at least one of the following three: Two amino acid sequences:
Val-Lys-Lys-Val-Leu-Gly-Asn-Pro;
Glu-Lys-Glu-Arg-Glu-Arg-Gln;
Lys-Arg-Gln-Lys-Tyr-Asp-Ile
Comprising a step of hydrolyzing to a polypeptide having
Consists of 5 to 10 amino acid residues and is an amino acid sequence of any one of the following 5:
Val-Lys-Lys-Val-Leu-Gly-Asn-Pro;
Val-Lys-Lys-Val-Leu-Gly-Asn-Pro-Ser-Asn;
Glu-Lys-Glu-Arg-Glu-Arg-Gln;
Lys-Arg-Gln-Lys-Tyr-Asp-Ile;
Lys-Arg-Gln-Lys-Tyr
The present invention relates to a method for producing an angiotensin-converting enzyme inhibitor, which comprises one or more of polypeptides having the following as an active ingredient.
[0026]
[0027]
Preferably, eight amino acids consisting of Val-Lys-Lys-Val-Leu-Gly-Asn-Pro, or 2 amino acids at the N-terminus or C-terminus of Val-Lys-Lys-Val-Leu-Gly-Asn-Pro The present invention relates to a food for preventing hypertension comprising, as an active ingredient, a polypeptide having myosin-derived angiotensin-converting enzyme inhibitory activity, comprising 10 amino acids to which 10 amino acid residues have been added.
[0028]
Alternatively, seven amino acids consisting of Glu-Lys-Glu-Arg-Glu-Arg-Gln or Lys-Arg-Gln-Lys-Tyr-Asp-Ile, or Glu-Lys-Glu-Arg-Glu-Arg- Glon or Lys-Arg-Gln-Lys-Tyr-Asp-Ile having 9 amino acids in which two amino acid residues are added to the N-terminal or C-terminal of the troponin T-derived angiotensin converting enzyme-inhibiting enzyme The present invention relates to a food for preventing hypertension containing a peptide as an active ingredient.
[0029]
BEST MODE FOR CARRYING OUT THE INVENTION
Hereinafter, the present invention will be described in detail.
[0030]
Polypeptide
The polypeptide in the present invention is a polypeptide consisting of 7 to 10 amino acid residues, having any one of the following three skeletons, and having angiotensin converting enzyme inhibitory activity.
Val-Lys-Lys-Val-Leu-Gly-Asn-Pro;
Glu-Lys-Glu-Arg-Glu-Arg-Gln;
Lys-Arg-Gln-Lys-Tyr-Asp-Ile.
[0031]
The polypeptide of the present invention is, specifically,
8 amino acids consisting of Val-Lys-Lys-Val-Leu-Gly-Asn-Pro,
10 amino acids obtained by adding two amino acid residues to the N-terminal or C-terminal of Val-Lys-Lys-Val-Leu-Gly-Asn-Pro;
Seven amino acids consisting of Glu-Lys-Glu-Arg-Glu-Arg-Gln or Lys-Arg-Gln-Lys-Tyr-Asp-Ile, or Glu-Lys-Glu-Arg-Glu-Arg-Gln or A polypeptide comprising nine amino acids with two amino acid residues added to the N-terminal or C-terminal of Lys-Arg-Gln-Lys-Tyr-Asp-Ile and having angiotensin converting enzyme inhibitory activity.
[0032]
It has now been found that polypeptides having the above skeleton have excellent angiotensin converting enzyme inhibitory activity.
[0033]
Here, Val-Lys-Lys-Val-Leu-Gly-Asn-Pro (VKKVLGNP) is a peptide derived from position 47 to position 54 from the myosin light chain (Davoli et al. Animal Biotechnology, 8: 179-185, 1997). It is. Among myosin-derived peptides, those having excellent angiotensin converting enzyme inhibitory activity such as the peptide have not been known so far.
[0034]
Glu-Lys-Glu-Arg-Glu-Arg-Gln (EKERERQ) and Lys-Arg-Gln-Lys-Tyr-Asp-Ile (KRQKYDI) are troponin T (Moir et al., Biochemical, January 16, 2017). -382, 1977).
[0035]
No troponin T-derived peptide having angiotensin converting enzyme inhibitory activity has been known so far.
[0036]
The polypeptide of the present invention can be obtained by hydrolyzing crude troponin (molecular weight range: about 14 to 31 kDa, including myosin light chain) with a proteolytic enzyme. As the partially purified troponin, those extracted from proteins derived from rabbits, cows, pigs and the like can be used.
[0037]
The crudely purified troponin is specifically obtained by performing the following purification. The ground meat washed with the low salt aqueous solution is made into acetone powder, from which it is extracted with a high salt buffer. Hydrochloric acid is added to the extract to adjust the pH to 4.6, and then the supernatant obtained by centrifugation is further adjusted to pH 7.0 with potassium hydroxide. Then, ammonium sulfate is added, and the fraction that precipitates at an ammonium sulfate concentration of 40% to 60% is collected. The precipitate is dialyzed using a buffer to obtain a crudely purified troponin.
[0038]
Examples of proteolytic enzymes include trypsin, chymotrypsin, pepsin and the like.
[0039]
The conditions for hydrolysis by the protease can be set as appropriate, but generally trypsin and chymotrypsin have a pH of 7.0 to 8.5, pepsin has a pH of 1 to 3, and the temperature is generally 25 to 37 ° C. is there.
[0040]
The polypeptide of the present invention is obtained by hydrolyzing crude troponin (molecular weight range: about 14 to 31 kDa, including myosin light chain) with a protein hydrolase, and then subjecting the product to ion exchange chromatography, gel filtration chromatography, reverse It is obtained by purifying by appropriately combining phase HPLC and the like.
[0041]
The polypeptide of the present invention may be synthesized by a known method such as Fmoc solid phase synthesis.
[0042]
Angiotensin converting enzyme inhibitor
The angiotensin converting enzyme inhibitor of the present invention is obtained by containing one or more of the above-mentioned polypeptides having angiotensin converting enzyme inhibitory activity as active ingredients. Specifically, it is an angiotensin converting enzyme inhibitor comprising one or two or more polypeptides consisting of 7 to 10 amino acid residues and having any one of the following three skeletons.
Val-Lys-Lys-Val-Leu-Gly-Asn-Pro;
Glu-Lys-Glu-Arg-Glu-Arg-Gln;
Lys-Arg-Gln-Lys-Tyr-Asp-Ile.
[0043]
In the angiotensin converting enzyme inhibitor of the present invention,
Val-Lys-Lys-Val-Leu-Gly-Asn-Pro;
Glu-Lys-Glu-Arg-Glu-Arg-Gln; or
A peptide having an angiotensin-converting enzyme inhibitory activity, which is obtained by adding an appropriate amino acid residue to the skeleton of Lys-Arg-Gln-Lys-Tyr-Asp-Ile or lacking an amino acid residue, is effective. Used as a component.
[0044]
For example, the present invention provides an angiotensin converting enzyme inhibitor comprising, as an active ingredient, one or more polypeptides having 5 to 10 amino acid residues and having any one of the following five backbones: Is included.
Val-Lys-Lys-Val-Leu-Gly-Asn-Pro;
Val-Lys-Lys-Val-Leu-Gly-Asn-Pro-Ser-Asn;
Glu-Lys-Glu-Arg-Glu-Arg-Gln;
Lys-Arg-Gln-Lys-Tyr-Asp-Ile;
Lys-Arg-Gln-Lys-Tyr.
[0045]
Here, Val-Lys-Lys-Val-Leu-Gly-Asn-Pro-Ser-Asn (VKKVLGNPSN) is one in which two amino residues are added to VKKVLGNNP, and 56 to 47 from the 47th position of the myosin light chain. Correspond to the rank.
[0046]
Further, Lys-Arg-Gln-Lys-Tyr (KRQKY) is obtained by deleting two amino acid residues from KRQKYDI.
[0047]
An angiotensin converting enzyme inhibitor can be obtained by appropriately formulating the polypeptide exemplified above as it is or together with a suitable carrier.
[0048]
As the carrier, a substance that is commonly used in the field of pharmaceuticals and that does not react with the polypeptide of the present invention can be used.
[0049]
Specifically, for example, lactose, glucose, mannitol, dextrin, cyclodextrin, starch, sucrose, magnesium metasilicate aluminate, synthetic aluminum silicate, sodium carboxymethylcellulose, hydroxypropyl starch, carboxymethylcellulose calcium, ion exchange resin, methylcellulose , Gelatin, gum arabic, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, polyvinyl alcohol, light anhydrous silicic acid, magnesium stearate, talc, tragacanth, bentonite, veegum, titanium oxide, sorbitan fatty acid ester, sodium lauryl sulfate, glycerin, Fatty acid glycerin ester, purified lanolin, glycerogelatin, polysorbate, macro Lumpur, vegetable oils, waxes, liquid paraffin, white petrolatum, fluorocarbons, nonionic surfactants, propylene glycol, water and the like. Dosage forms include tablets, capsules, granules, powders, syrups, suspensions, suppositories, ointments, creams, gels, patches, inhalants, injections, and the like. In the case of a liquid preparation, it may be in the form of being dissolved or suspended in water or another appropriate medium at the time of use. Tablets and granules may be coated by a known method. In the case of an injection, the polypeptide may be dissolved in water, physiological saline, a glucose solution, or the like. Further, a buffer and a preservative may be added.
[0050]
The content of the polypeptide in the angiotensin converting enzyme inhibitor of the present invention can be appropriately set as desired, but is contained at a rate of about 0.0001 to 100%, preferably about 0.01 to 10%.
[0051]
The angiotensin converting enzyme inhibitor of the present invention may contain other components having a hypotensive effect and various additives.
[0052]
The angiotensin-converting enzyme inhibitor of the present invention can exert an antihypertensive action and an inhibitory action on bradykinin inactivation, so that essential hypertension, renal hypertension, a preventive or therapeutic agent for hypertension such as adrenal hypertension, an agent for angina attack, It can be used as an agent for improving a pathological condition in an increase in threshold value, a decrease in myocardial infarction, and congestive heart failure.
[0053]
Foods for preventing hypertension
The food for preventing hypertension of the present invention can be obtained by incorporating the polypeptide of the present invention or the angiotensin converting enzyme inhibitor into a suitable foodstuff.
[0054]
Examples of the food materials include pork, beef, rabbit (rabbit), lamb, goat, horse, chicken, turkey, quail, whale, shark, fish such as cod and salmon.
[0055]
Food forms include processed meat products such as sausages, hams, hamburgers, meatballs, curry, croquettes, fried chicken, spring rolls, rolled cabbage, and other prepared foods, soups, energy drinks, jelly, ice cream, etc. Desserts, snacks / confectionery, tablet-type nutritionally functional foods, mixed seasonings such as fried powder, powder seasonings, and the like.
[0056]
In the food of the present invention, the above-mentioned polypeptide or angiotensin converting enzyme inhibitor having any amino acid skeleton can be used alone or in combination of two or more.
[0057]
The content of the polypeptide or the angiotensin converting enzyme inhibitor in the food of the present invention can be appropriately set as desired, but is about 0.0001 to 99%, preferably about 0.01 to 10% as the polypeptide. .
[0058]
In the food of the present invention, other components having an antihypertensive action and additives generally used in foods, for example, preservatives such as sorbic acid, binding reinforcing agents such as phosphates, thickeners such as carrageenan, vitamin C And a coloring agent such as sodium nitrite, a stabilizer, an antioxidant, an anti-caking agent, and the like.
[0059]
Since the food of the present invention contains the above-mentioned polypeptide and an angiotensin converting enzyme inhibitor containing the polypeptide, it has angiotensin converting enzyme (ACE) inhibitory activity and angiotensin II having a strong blood pressure increasing action. It exerts a blood pressure lowering effect based on the effect of inhibiting the degradation of bradykinin, which has a conversion inhibiting effect and a blood pressure lowering effect.
[0060]
Due to such properties, the present invention can be suitably used as a food for preventing hypertension such as essential hypertension, renal hypertension, and adrenal hypertension.
[0061]
【Example】
Hereinafter, the present invention will be described specifically with reference to Examples, but the present invention is not limited to these Examples.
[0062]
Example 1
Crude troponin (molecular weight range: about 14 to 31 kDa) extracted from domestic pork loin was hydrolyzed with pepsin. The partially purified troponin was obtained by performing the following purification. The ground meat washed with a low salt aqueous solution (1% Triton X-100, 50 mM potassium chloride, 5 mM tris (hydroxymethyl) aminomethane, pH 8.0) was converted into acetone powder, and a high salt buffer (1 M) was added thereto. It was extracted with a solution of potassium chloride, 25 mM tris (hydroxymethyl) aminomethane, 0.1 mM calcium chloride, 0.1 mM dithiothreitol, 1 mM sodium azide, pH 8.0). Hydrochloric acid was added to the extract to adjust the pH to 4.6, then the supernatant obtained by centrifugation was further adjusted to pH 7.0 with potassium hydroxide, and ammonium sulfate was added. Fractions that precipitated in were collected. The precipitate was dialyzed against a buffer (2 mM tris (hydroxymethyl) aminomethane, 0.5 mM dithiothreitol, 2 mM sodium azide, pH 7.5) to obtain a crude purified troponin.
[0063]
In addition, it was confirmed by polyacrylamide electrophoresis that the partially purified troponin contained a myosin light chain (molecular weight: about 15 to 26 kDa). 50% inhibitory activity of this crude troponin pepsin hydrolyzate on ACE from bovine lung (IC50) Was 225 mg / ml. Since no ACE inhibitory activity was observed for unhydrolyzed troponin, it was presumed that the expression of the activity was derived from the peptide generated by pepsin degradation.
[0064]
Hereinafter, in Example 1, 50% inhibitory activity against angiotensin converting enzyme (ACE) (IC50) Was measured by the method of Cushman-Cheng (Biochemical Pharmacology, 20: 1637-1648, 1971) using ACE derived from bovine lung.
[0065]
The hydrolyzate was first subjected to anion exchange chromatography using a DE53 column (Whatman International Ltd., Kent, UK) (16 × 150 mm). That is, the hydrolyzate was applied with 20 mM tris (hydroxymethyl) aminomethane (adjusted to pH 7.5 with acetic acid), and a gradient (0-300 mM) elution was performed with an aqueous NaCl solution containing the same buffer. . The flow rate was 1.13 ml / min. After fractionation every 7 minutes (7.91 ml), the absorbance at 215 nm and 280 nm was measured (FIG. 1). The obtained fraction was subjected to SEP-PAK PlusC18The salt was desalted using a cartridge (Waters Co., Milford, Mass., USA), the adsorbed fraction was eluted with 50% acetonitrile, the obtained fraction was concentrated, and the activity was measured. Particularly strong activity was observed in the fraction (IC50 = 201 mg / ml). This active fraction is used for Cosmoseal 5C18 AR-II (4.5 × 150 mm) (Nacalai Tesque Inc., Kyoto, Japan) subjected to reverse phase (RP) -HPLC and 1-80 of acetonitrile containing 0.1% trifluoroacetic acid (TFA). % Elution (flow rate 0.5 ml / min) and the absorbance at 215 nm was monitored (FIG. 2). The absorbance at 215 nm was also measured in the subsequent purification steps.
[0066]
Next, the fraction 5 (IC50 = 138 mg / ml) with Cosmoseal 5C18 RP-HPLC using AR-II (4.5 × 150 mm) (Nacalai Tesque), 12% CH containing 0.1% TFA3Isocratic elution was performed with CN (flow rate: 0.5 ml / min) (FIG. 3). The active fractions A and B obtained here were combined with TSK-gel G2000SW.XL (7.8 x 300 mm) Each was subjected to gel filtration HPLC using (Tosoh Co., Tokyo, Japan) and isocratic elution with 20 mM sodium phosphate (pH 7.0) (flow rate 0.5 ml / min) (FIG. 4). The highly active fraction obtained here (derived from A: IC50 = 119 mg / ml, from B: IC50 = 27 mg / ml) was subjected to RP-HPLC using Cosmoseal 5PE-MS (4.6 x 250 mm) (Nacalai Tesque) and 12% CH containing 0.1% TFA.3Isocratic elution was carried out with CN (flow
[0067]
Further, the fraction 7 (IC50 = 114 mg / ml) with Cosmoseal 5C18 RP-HPLC using AR-II (4.5 × 150 mm) (Nacalai Tesque), 16% CH containing 0.1% TFA3Isocratic elution was performed with CN (flow rate: 0.5 ml / min) (FIG. 6). The active fraction L obtained here was used for TSK-gel G2000SW.XL The gel was subjected to gel filtration HPLC using (7.8 × 300 mm) (Tosoh), and subjected to isocratic elution (flow rate: 0.5 ml / min) with 20 mM sodium phosphate (pH 7.0) (FIG. 7). . The highly active fraction obtained here (derived from L: IC50 = 57 mg / ml) was subjected to RP-HPLC using Cosmoseal 5PE-MS (4.6 x 250 mm) (Nacalai Tesque) and 15% CH containing 0.1% TFA.3Isocratic elution was carried out with CN (flow
[0068]
The amino acid sequence of the fraction obtained by the purification was subjected to sequence analysis using a protein sequencer Procise 492 (Applied Biosystems, Foster City, CA, USA). As a result, it was confirmed that the peptide obtained from Fraction A was VKKVLGNP, the peptide obtained from Fraction B was EKERERQ, and the peptide obtained from Fraction L was KRQKYDI. These peptides were novel ACE inhibitory peptides that had not been reported before.
These amino acid sequences were searched for in the database SwissProt (EMBL Outstation-European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK), and the K position at the 47th position of the pigs in the K-position was the K-position from the K-line to the K-position in the 47th position, and the K-position was the same as the K-position in the K-line. The protein was found to be derived from myosin light chain (molecular weight: about 15 to 26 kDa) contained in the crude troponin used as the material. EKERERQ and KRQKYDI were consistent with peptides contained in rabbit, bovine, rat, human and mouse skeletal muscle troponin T.
[0069]
The crude troponin (molecular weight range: about 14 to 31 kDa, including myosin light chain) used in the present invention is derived from porcine skeletal muscle. I haven't. Although the amino acid sequence of porcine troponin C has been registered in the database, the amino acid sequences of troponin I and troponin T have not been registered, and a sequence completely matching the peptide of the present invention could not be found. However, since the amino acid sequence of troponin in animals other than pigs was registered in the database, it was searched whether the peptide obtained in this study was present in these troponins. As a result, EKERERRQ was found to be rabbit (residues 120 to 126), bovine (residues 120 to 126), rat (residues 102 to 108), human (residues 112 to 118), and mouse (residues 112 to 118). (Residue 110) was present in troponin T. KRQKYDI is rabbit (residues 230 to 236), bovine (residues 230 to 236), rat (residues 212 to 218), human (residues 222 to 228), and mouse (residues 214 to 220). Troponin T). From these facts, it was recognized that a peptide having the same sequence was also present in porcine troponin T. Since the peptide found in this study was obtained using pork as a material, it was considered that it was derived from troponin T. Estimated.
[0070]
Example 2
The three ACE-inhibiting peptides identified in Example 1 and their related peptides, VKKVLGNPSN (corresponding to positions 47 to 56 of pig myosin light chain) and KRQKY (corresponding to positions 230 to 234 of rabbit troponin T), were Fmoc. It was synthesized by solid phase synthesis.
[0071]
ACE Evaluation of inhibitory activity
IC of peptide prepared in Example 250, Molecular weight, and 5-55% (20 min) gradient elution of acetonitrile containing 0.1% TFA by RP-HPLC ((TSKgel ODS-80TS, 4.5 × 250 mm, Tosoh) (flow
[0072]
In Example 2, 50% inhibitory activity against ACE (IC50) Was measured by the method of Cushman-Cheung (Biochemical Pharmacology, 20: 1636-1648, 1971) using ACE derived from rabbit lung.
[0073]
[Table 1]
[0074]
【The invention's effect】
The present invention provides a polypeptide having a novel angiotensin converting enzyme (ACE) inhibitory activity, which is obtained from troponin and myosin, which are muscle proteins abundantly contained in pork and beef.
[0075]
The polypeptide or the angiotensin converting enzyme inhibitor of the present invention not only has remarkable angiotensin converting enzyme inhibitory activity, but also can be obtained by decomposing a protein derived from natural meat using a digestive enzyme which is also present in a living body. Therefore, its safety is high and its toxicity is low.
[0076]
Due to such properties, the polypeptide or angiotensin converting enzyme inhibitor of the present invention is not only useful as a pharmacological component for medicine, but also has a high value-added functionality such as a food for preventing hypertension having a hypotensive action and the like. It is also useful as a material for making food.
[Brief description of the drawings]
FIG. 1 is a diagram showing a chromatogram obtained when anion exchange chromatography is performed using a pepsin hydrolyzate of a partially purified troponin as a sample.
FIG. 2 shows the active fraction shown in FIG. 1 in Cosmosil 5C18 It is a figure which shows the chromatogram at the time of being provided to the reverse phase high performance liquid chromatography using AR-II.
FIG. 3 shows the
FIG. 4 shows that the active fractions A and B shown in FIG. 3 were separately treated with TSK-gel G2000SW.XLFIG. 6 is a view showing a chromatogram when subjected to gel filtration high-performance liquid chromatography using a.
FIG. 5 shows chromatograms obtained when the two active fractions (derived from fractions A and B) shown in FIG. 4 were subjected to reversed-phase high-performance liquid chromatography using Cosmoseal 5PE-MS. FIG.
FIG. 6 shows that the active fraction 7 shown in FIG.18 It is a figure which shows the chromatogram at the time of being provided to the reverse phase high performance liquid chromatography using AR-II.
FIG. 7 shows that the active fraction L shown in FIG. 6 was transferred to TSK-gel G2000SW.XLFIG. 6 is a view showing a chromatogram when subjected to gel filtration high-performance liquid chromatography using a.
FIG. 8 is a view showing a chromatogram obtained when the active fraction (derived from fraction L) shown in FIG. 7 was subjected to reversed-phase high-performance liquid chromatography using Cosmoseal 5PE-MS.
Claims (5)
Val−Lys−Lys−Val−Leu−Gly−Asn−Pro;
Glu−Lys−Glu−Arg−Glu−Arg−Gln;
Lys−Arg−Gln−Lys−Tyr−Asp−Ile。A polypeptide comprising 7 to 10 amino acid residues and having any one of the following three amino acid sequences and having angiotensin converting enzyme inhibitory activity:
Val-Lys-Lys-Val-Leu-Gly-Asn-Pro;
Glu-Lys-Glu-Arg-Glu-Arg-Gln;
Lys-Arg-Gln-Lys-Tyr-Asp-Ile.
Val−Lys−Lys−Val−Leu−Gly−Asn−Pro;
Val−Lys−Lys−Val−Leu−Gly−Asn−Pro−Ser−Asn;
Glu−Lys−Glu−Arg−Glu−Arg−Gln;
Lys−Arg−Gln−Lys−Tyr−Asp−Ile;
Lys−Arg−Gln−Lys−Tyr。An angiotensin converting enzyme inhibitor comprising a polypeptide consisting of 5 to 10 amino acid residues and having any one of the following five amino acid sequences as one or more active ingredients.
Val-Lys-Lys-Val-Leu-Gly-Asn-Pro;
Val-Lys-Lys-Val-Leu-Gly-Asn-Pro-Ser-Asn;
Glu-Lys-Glu-Arg-Glu-Arg-Gln;
Lys-Arg-Gln-Lys-Tyr-Asp-Ile;
Lys-Arg-Gln-Lys-Tyr.
Val−Lys−Lys−Val−Leu−Gly−Asn−Pro;
Glu−Lys−Glu−Arg−Glu−Arg−Gln;
Lys−Arg−Gln−Lys−Tyr−Asp−Ile。Crude troponin (molecular weight range of about 14 to 31 kDa, including myosin light chain) is composed of 7 to 10 amino acid residues using a protease, and has at least one of the following three amino acid sequences: A method for producing an angiotensin converting enzyme inhibitor, comprising a step of hydrolyzing to a polypeptide.
Val-Lys-Lys-Val-Leu-Gly-Asn-Pro;
Glu-Lys-Glu-Arg-Glu-Arg-Gln;
Lys-Arg-Gln-Lys-Tyr-Asp-Ile.
Val−Lys−Lys−Val−Leu−Gly−Asn−Pro;
Val−Lys−Lys−Val−Leu−Gly−Asn−Pro−Ser−Asn;
Glu−Lys−Glu−Arg−Glu−Arg−Gln;
Lys−Arg−Gln−Lys−Tyr−Asp−Ile;
Lys−Arg−Gln−Lys−Tyr。4. The angiotensin converting enzyme inhibitor comprises 5 to 10 amino acid residues, and contains one or more polypeptides having any one of the following five amino acid sequences as an active ingredient. Production method described in 1.
Val-Lys-Lys-Val-Leu-Gly-Asn-Pro;
Val-Lys-Lys-Val-Leu-Gly-Asn-Pro-Ser-Asn;
Glu-Lys-Glu-Arg-Glu-Arg-Gln;
Lys-Arg-Gln-Lys-Tyr-Asp-Ile;
Lys-Arg-Gln-Lys-Tyr.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003008131A JP4221571B2 (en) | 2003-01-16 | 2003-01-16 | Angiotensin converting enzyme inhibitor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003008131A JP4221571B2 (en) | 2003-01-16 | 2003-01-16 | Angiotensin converting enzyme inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004217588A true JP2004217588A (en) | 2004-08-05 |
JP4221571B2 JP4221571B2 (en) | 2009-02-12 |
Family
ID=32898025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003008131A Expired - Lifetime JP4221571B2 (en) | 2003-01-16 | 2003-01-16 | Angiotensin converting enzyme inhibitor |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4221571B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007045794A (en) * | 2005-08-12 | 2007-02-22 | Prima Meat Packers Ltd | Antifatigue peptide derived from edible meat protein |
-
2003
- 2003-01-16 JP JP2003008131A patent/JP4221571B2/en not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007045794A (en) * | 2005-08-12 | 2007-02-22 | Prima Meat Packers Ltd | Antifatigue peptide derived from edible meat protein |
Also Published As
Publication number | Publication date |
---|---|
JP4221571B2 (en) | 2009-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102177173B (en) | Collagen peptide, dipeptide, and agent for prevention of disease | |
CA2825157C (en) | Therapeutic or preventive agent for diabetes | |
Fu et al. | Separation of angiotensin I‐converting enzyme inhibitory peptides from bovine connective tissue and their stability towards temperature, p H and digestive enzymes | |
Katayama et al. | Purification and characterization of an angiotensin I‐converting enzyme inhibitory peptide derived from porcine troponin C | |
Katayama et al. | Angiotensin I-converting enzyme inhibitory activities of porcine skeletal muscle proteins following enzyme digestion | |
JP4834671B2 (en) | Composition effective for prevention and treatment of adult diseases | |
Bhat et al. | Antihypertensive peptides from animal proteins | |
JP4790325B2 (en) | Antihypertensive peptide derived from meat protein | |
JP3093378B2 (en) | Method for producing composition containing angiotensin converting enzyme inhibitor | |
JP4221571B2 (en) | Angiotensin converting enzyme inhibitor | |
JP3893616B2 (en) | Angiotensin converting enzyme inhibitor | |
CA2195053C (en) | Agents for inhibiting accumulation of visceral fat | |
JP3651878B2 (en) | Antihypertensive peptide derived from meat protein | |
JP4470152B2 (en) | Novel tripeptide and method for producing the same | |
JP3110075B2 (en) | Method for producing composition containing angiotensin converting enzyme inhibitor | |
JP4429031B2 (en) | Angiotensin converting enzyme inhibitory peptide | |
JP4106539B2 (en) | Angiotensin converting enzyme inhibitory peptide | |
JP3943459B2 (en) | Angiotensin converting enzyme inhibitory peptide | |
KR100600578B1 (en) | Composition for anti-hypertension containing hydrolysates from Yellowfin sole | |
JP2002121199A (en) | New peptide and method for producing the same | |
JP3454545B2 (en) | Angiotensin I converting enzyme inhibiting tripeptide, method for producing the same, and food containing the same | |
JPH06220088A (en) | Tripeptide inhibiting angiotensin i converting enzyme, its production and food containing the tripeptide | |
KR20230110311A (en) | A novel angiotensin I converting enzyme (ACE) inhibitory peptide | |
Mizuta et al. | Characterization of a major alpha component of collagen from muscle of antarctic krill Euphausa superba | |
Abdulazeez et al. | Isolation and Characterization of a New Angiotensin-converting Enzyme Inhibitory Peptide from Heterobronchus bidorsalis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051014 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080723 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080910 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20081015 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20081104 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4221571 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111128 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111128 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121128 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121128 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131128 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |